Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398697 · ClinicalTrials.gov registry record · Phase 1
Phase I Perifosine and Gemcitabine Study
A Phase 1 study, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00398697 is a Phase 1 study that has completed, run by AEterna Zentaris. The registered enrollment target is 19 participants.
The verdict
NCT00398697, a Phase 1 study, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a study of the drug perifosine in combination with Gemcitabine. Perifosine is an oral anti-cancer agent that has been used in more than 140 people, but has not been combined with other drugs before this study. The study is designed to determine the highest dose of perifosine that can be administered to people every day while they are on a Gemcitabine regimen, without severe or prolonged nausea, vomiting and diarrhea. This study starts with patients taking 50 mg/day and goes up to 150 mg/day. After the highest tolerable dose is found, we will add 10 more patients at that dose.
Interventions
- DRUG Gemcitabine
- DRUG Perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2004-08 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00398697
The ClinicalTrials.gov registry entry for NCT00398697 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00398697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00398697 about?
NCT00398697 is a clinical study titled "Phase I Perifosine and Gemcitabine Study". This is a study of the drug perifosine in combination with Gemcitabine. Perifosine is an oral anti-cancer agent that has been used in more than 140 people, but has not been combined with other drugs before this study. The study is designed to determine the highest dose of perifosine that can be admi...
What is the current status of trial NCT00398697?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2004-08. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00398697?
The interventions under investigation include: Gemcitabine (DRUG), Perifosine (DRUG).
Who is sponsoring clinical trial NCT00398697?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.